Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 29, 2021 10:47am
175 Views
Post# 33936566

RE:Lowering expectations on efficacy???

RE:Lowering expectations on efficacy???I just quickly re-listened to the relevant part about the preliminary efficacy and Paul noted that if they see it they will "tout it to Wall Street and our investors". No timing was mentioned on when they would tout it but I really do not think anything has changed on this front yet. Conceivably, the efficacy might not be seen until the last patient and they would need a few months to track that patient (and hopefully that patient would survice long enough to continue the cycles of treatment needed) and that might place any preliminary efficacy news until after year-end. But it was not clear and it was something he should have been trying to make clearer, not muddier.

Since the trial is clearly still ongoing based on his comments, the chances of an efficacy signal seem pretty high to me. And if they ahve already seen one or expect to see one, you know they will want to get all the info they can on it before touting it as they would not want to tout and then backtrack. 

qwerty22 wrote: Not strong.

Also. He's clearly not prep'd to talk on market opportunity.


<< Previous
Bullboard Posts
Next >>